Butler University | 2003 | Pharm.D.
Dr. Marc Scheetz attained a Doctorate of Pharmacy from Butler University, earned a Masters of Science in Clinical Investigation degree at Northwestern University, and completed his pharmacy practice residency and an infectious diseases fellowship at Northwestern Memorial Hospital. Dr. Scheetz is a Professor at Midwestern University in the Chicago College of Pharmacy and holds a joint appointment in the Department of Pharmacology, College of Graduate Studies. Dr. Scheetz is the Director of the Pharmacometric Center of Excellence at Midwestern University. He currently practices clinically as an infectious diseases pharmacist at Northwestern Memorial Hospital in downtown Chicago, IL and serves as the Director for the Post-Doctoral Fellowship Program in Infectious Diseases Pharmacotherapy.
Dr. Scheetz has authored over 160 original research manuscripts and review articles in the area of anti-infective pharmacokinetics and pharmacodynamics and currently serves as a reviewer for several infectious diseases, pharmacy, and medical journals. His primary research interest lies in the interface of the pharmacokinetic/pharmacodynamic interaction (i.e. between antimicrobials, pathogens, and hosts). He is particularly interested in assessing modifiable pharmacologic variables in the treatment of infectious diseases and identifying optimal exposures against the backdrop of toxicity. His group studies toxicology in the laboratory as well as through clinical data modeling. Dr. Scheetz is actively engaged in local and national leadership positions and formerly served as a member of the FDA Antimicrobial Drugs Advisory Committee.
Downers Grove, IL
College of Pharmacy
Downers Grove Campus
College of Graduate Studies - IL
Butler University | 2003 | Pharm.D.
Select Publications (out of >160 peer reviewed manuscripts)
1. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131-3. Epub 2013/07/10. doi: 10.1128/AAC.00607-13. PubMed PMID: 23836188; PMCID: PMC3811461.
2. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(5):1621-6. Epub 2007/02/20. doi: 10.1128/AAC.01099-06. PubMed PMID: 17307973; PMCID: PMC1855572.
3. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52(6):2256-9. Epub 2008/04/09. doi: 10.1128/AAC.00070-08. PubMed PMID: 18391028; PMCID: PMC2415807.
4. Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH. Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. Antimicrob Agents Chemother. 2016;60(10):5742-51. Epub 2016/07/20. doi: 10.1128/AAC.00591-16. PubMed PMID: 27431226; PMCID: PMC5038238.
5. Avedissian SN, Pais GM, O'Donnell JN, Lodise TP, Liu J, Prozialeck WC, Joshi MD, Lamar PC, Becher L, Gulati A, Hope W, Scheetz MH. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother. 2019;74(8):2326-34. Epub 2019/05/09. doi: 10.1093/jac/dkz167. PubMed PMID: 31065686; PMCID: PMC6640290.
6. Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. Clin Infect Dis. 2019;69(11):1881-7. Epub 2019/02/05. doi: 10.1093/cid/ciz051. PubMed PMID: 30715208; PMCID: PMC6853683.
7. Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury. Antimicrob Agents Chemother. 2019;63(7). Epub 2019/04/17. doi: 10.1128/AAC.00079-19. PubMed PMID: 30988153; PMCID: PMC6591602.
8. Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d'Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. 2020;75(5):1228-36. Epub 2020/02/06. doi: 10.1093/jac/dkz563. PubMed PMID: 32011685.
9. Pais GM, Liu J, Zepcan S, Avedissian SN, Rhodes NJ, Downes KJ, Moorthy GS, Scheetz MH. Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. Pharmacotherapy. 2020;40(5):438-54. Epub 2020/04/03. doi: 10.1002/phar.2388. PubMed PMID: 32239518; PMCID: PMC7331087.
10. Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH. Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction? Clin Infect Dis. 2020;71(2):426-32. Epub 2019/12/14. doi: 10.1093/cid/ciz1189. PubMed PMID: 31833540.
2012 Young Investigator of the Year, Society of Infectious Diseases Pharmacists
2018 Elected Fellow of the American College of Clinical Pharmacy (FCCP)
The following assays have been developed by our group for Research Use Only:
atenolol, azithromycin, cefepime, ceftazidime,colistin, creatinine, dalbavancin, iohexol, meropenem, micafungin, piperacillin, polymyxin B, sulbactam, tazobactam, vancomycin.
Please contact Dr. Scheetz for more information.